CA2205771A1 - Improved delivery of disease modifiers - Google Patents
Improved delivery of disease modifiersInfo
- Publication number
- CA2205771A1 CA2205771A1 CA002205771A CA2205771A CA2205771A1 CA 2205771 A1 CA2205771 A1 CA 2205771A1 CA 002205771 A CA002205771 A CA 002205771A CA 2205771 A CA2205771 A CA 2205771A CA 2205771 A1 CA2205771 A1 CA 2205771A1
- Authority
- CA
- Canada
- Prior art keywords
- improved delivery
- disease modifiers
- disease
- hyaluronan
- modifiers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A pharmaceutical composition component comprising hyaluronan binding motif (HBM) interposed between a form of hyaluronan having a molecular weight (protein standard) less than 750,000 daltons and a disease modifier which comprises a peptide or protein.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002205771A CA2205771C (en) | 1997-05-22 | 1997-05-22 | Improved delivery of disease modifiers |
AU73286/98A AU740631B2 (en) | 1997-05-22 | 1998-05-11 | Improved delivery of disease modifiers |
EP98920426A EP0998297A2 (en) | 1997-05-22 | 1998-05-11 | Improved delivery of disease modifiers |
JP54972998A JP2001526666A (en) | 1997-05-22 | 1998-05-11 | Improved release of disease modulators |
NZ501270A NZ501270A (en) | 1997-05-22 | 1998-05-11 | Pharmaceutical composition comprising hyaluronan (Mr less than 750,00) and a disease modifier (cytokine, a peptide mimicking a cytokine or a protein mimicking a cytokine) to enhance delivery of disease modifiers |
PCT/CA1998/000448 WO1998052590A2 (en) | 1997-05-22 | 1998-05-11 | Improved delivery of disease modifiers |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002205771A CA2205771C (en) | 1997-05-22 | 1997-05-22 | Improved delivery of disease modifiers |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2205771A1 true CA2205771A1 (en) | 1998-11-22 |
CA2205771C CA2205771C (en) | 2002-05-14 |
Family
ID=4160694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002205771A Expired - Fee Related CA2205771C (en) | 1997-05-22 | 1997-05-22 | Improved delivery of disease modifiers |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0998297A2 (en) |
JP (1) | JP2001526666A (en) |
AU (1) | AU740631B2 (en) |
CA (1) | CA2205771C (en) |
NZ (1) | NZ501270A (en) |
WO (1) | WO1998052590A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6875753B1 (en) | 1996-03-14 | 2005-04-05 | The Governors Of The University Of Alberta | Methods for cell mobilization using in vivo treatment with hyaluronan (HA) |
US20030082586A1 (en) | 1999-06-29 | 2003-05-01 | Millennium Pharmaceuticals, Inc. | Antibodies having diagnostic, preventive, therapeutic, and other uses |
CA2406593A1 (en) * | 2000-04-20 | 2001-11-01 | Cangene Corporation | Rhamm peptide conjugates |
JP2007535486A (en) * | 2003-05-07 | 2007-12-06 | ラ ホーヤ インスティチュート フォー モレキュラー メディシン | Method for promoting functional recovery of endogenous or implanted or transplanted stem cells using high molecular weight hyaluronic acid |
DE102011122236A1 (en) * | 2011-12-09 | 2013-06-13 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Composition useful e.g. in topical treatment of inflammatory diseases of skin and/or mucous membrane, comprises fusafungine and its derivate, and acidic glycosaminoglycan or its derivatives |
FR3002452B1 (en) * | 2013-02-28 | 2016-02-12 | Dermaconcept Jmc | TOPIC ANTIMICROBIAL DERMATOLOGICAL COMPOSITION |
PE20181363A1 (en) | 2015-09-23 | 2018-08-27 | Genentech Inc | OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
GB9207949D0 (en) * | 1992-04-09 | 1992-05-27 | Univ Manitoba | Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility |
HUT76846A (en) * | 1994-08-30 | 1997-12-29 | Hyal Pharma Corp | Hyaluronic acid and derivatives for modulation of cellular activity |
-
1997
- 1997-05-22 CA CA002205771A patent/CA2205771C/en not_active Expired - Fee Related
-
1998
- 1998-05-11 WO PCT/CA1998/000448 patent/WO1998052590A2/en not_active Application Discontinuation
- 1998-05-11 JP JP54972998A patent/JP2001526666A/en active Pending
- 1998-05-11 AU AU73286/98A patent/AU740631B2/en not_active Ceased
- 1998-05-11 NZ NZ501270A patent/NZ501270A/en unknown
- 1998-05-11 EP EP98920426A patent/EP0998297A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO1998052590A3 (en) | 1999-04-22 |
CA2205771C (en) | 2002-05-14 |
AU740631B2 (en) | 2001-11-08 |
EP0998297A2 (en) | 2000-05-10 |
WO1998052590A2 (en) | 1998-11-26 |
NZ501270A (en) | 2001-08-31 |
AU7328698A (en) | 1998-12-11 |
JP2001526666A (en) | 2001-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0809996A3 (en) | Interferon conjugates | |
BG102714A (en) | Pharmaceutical composition for immunomodulation based on peptides and adjuvants | |
CA2333145A1 (en) | Drug delivery system comprising a homeobox peptide and a non-peptide, non-nucleotide drug | |
HK1029124A1 (en) | Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them. | |
WO1997038689A3 (en) | Enteric-coated pharmaceutical compositions of mycophenolate | |
EP1304346A3 (en) | Conjugate of polyethylene glycol and chitosan | |
EP0875252A3 (en) | Activated protein C formulations | |
CA2191088A1 (en) | Copolymer-1 improvements in compositions of copolymers | |
AU1180997A (en) | Novel taxoids, their preparation and pharmaceutical compositions containing them | |
HK1027957A1 (en) | Pharmaceutical composition. | |
ZA974735B (en) | Pharmaceutical compositions. | |
CA2223567A1 (en) | Modified meningococcal polysaccharide conjugate vaccines | |
HK1047584A1 (en) | Benzopyrans and benzoxepines, pharmaceutical compositions comprising them and preparation process. | |
WO1999040112A8 (en) | Neuroprotective peptides and uses thereof | |
CA2263181A1 (en) | Anti-chlamydial methods and materials | |
HRP950612B1 (en) | PEPTIDE p277 ANALOGS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | |
EP0950708A3 (en) | Enhanced affinity hyaluronan binding peptides | |
WO2002056833A3 (en) | Preparation of a therapeutic composition | |
ZA989680B (en) | Pharmaceutical composition. | |
CA2205771A1 (en) | Improved delivery of disease modifiers | |
CA2191872A1 (en) | Beta sheet forming peptides and gels made thereof | |
HK1029928A1 (en) | Pharmaceutical compositions of peptides having lowsolubility in physiological medium. | |
ZA971746B (en) | Taxoids, their preparation and pharmaceutical compositions containing them. | |
HK1022853A1 (en) | Pharmaceutical compositions. | |
CA2126241A1 (en) | Sulphated polysaccharide, preparation thereof, pharmaceutical composition and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |